GlassScriptPhysician profile
Sanjay Kamat
NPI 1205886421
$5,893.19
in general payments reported to CMS, 2019-2025
22 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $233 · 2021: $1,963 · 2022: $1,510 · 2023: $1,031 · 2024: $424 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $975.89 | 2021-2024 | Hydrus Microstent, Eysuvis, Clareon |
| Ivantis, INC | $776.14 | 2020-2021 | |
| Glaukos Corporation | $582.15 | 2021-2025 | Iaccess Precision Blade, Idosetr |
| Sun Pharmaceutical Industries INC. | $556.07 | 2019-2025 | Cequa |
| Abbvie INC. | $460.82 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $424.37 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $421.49 | 2019-2021 | |
| Sight Sciences, INC. | $233.30 | 2022-2024 | Omni Surgical System |
| New World Medical,INC. | $202.48 | 2024-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Allergan, INC. | $167.99 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $161.57 | 2022-2025 | Miebo, Vyzulta, Scoutpro Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $156.89 | 2019-2020 | |
| Alimera Sciences, INC. | $144.00 | 2021-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Omeros Corporation | $103.74 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $103.30 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $102.50 | 2022 | |
| Oyster Point Pharma, INC. | $82.67 | 2022 | |
| Ocular Therapeutix, INC. | $49.17 | 2024-2025 | Dextenza |
| Eyevance Pharmaceuticals LLC | $28.49 | 2019-2023 | Flarex |
| Oasis Medical, INC. | $18.49 | 2019 | |
| Eyepoint US, INC. | $16.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Kamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.